Critical response Review aggregation website
Rotten Tomatoes gives
Extraordinary Measures an approval rating of 29% based on reviews from 142 critics and an average rating of 4.88 out of 10. The site's general consensus is, "Despite a timely topic and a pair of heavyweight leads,
Extraordinary Measures never feels like much more than a made-for-TV tearjerker."
Metacritic, which assigns a
weighted average score out of 0–100 reviews from film critics, has a rating score of 45 based on 33 reviews. Audiences polled by
CinemaScore gave the film an average grade of "A-" on an A+ to F scale.
Richard Corliss of
Time magazine wrote: "Fraser keeps the story anchored in reality. Meredith Droeger does too: as the Crowleys' afflicted daughter, she's a smart little bundle of fighting spirit. So is the movie, which keeps its head while digging into your heart. You have this critic's permission to cry in public."
The New York Times A. O. Scott said in his review: "The startling thing about
Extraordinary Measures is not that it moves you. It's that you feel, at the end, that you have learned something about the way the world works." Ramona Bates MD, writing for the health news organisation, EmaxHealth, stated that the film brings attention to
Pompe disease. Peter Rainer from
The Christian Science Monitor mentions that
Big Pharma got a surprisingly free pass in the film and that it will come as a surprise to all those sufferers struggling to get
orphan drugs developed. Jef Akst, writing for the journal
The Scientist, stated that the film is good depiction of the "hard to swallow fiscal issues of
drug development."
Box office The film opened at #8 on its opening weekend, taking in $6 million. The film remained in theaters for four weeks, earning $12 million. ==References==